CUMBERLAND PHARMACEUTICALS APPOINTS MARTIN BROWN JR. TO ITS BOARD OF DIRECTORS
Retrieved on:
Tuesday, July 19, 2022
The Land Trust, Research, CEO, Vanderbilt University Medical Center, KPMG, Brown–Forman, WNPT (TV), Cumberland School of Law, Lawyer, Woodford Reserve, Rheumatology, Board of directors, Jack Daniel's, New, Adams, RCA Records Nashville, Yale University, Gastroenterology, NASDAQ, Board, Multimedia, The Nature Conservancy, Acadia Healthcare, WPLN-FM, Sony Music Nashville, Health, Partnership, Montgomery Bell Academy, FDA, Vanderbilt University, Pharmaceutical industry, Property management, Management, BenRiach distillery, Ali Kazimi
NASHVILLE, Tenn., July 19, 2022 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company, announced today that Martin Brown Jr. has joined the company's Board of Directors.
Key Points:
- NASHVILLE, Tenn., July 19, 2022 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company, announced today that Martin Brown Jr. has joined the company's Board of Directors.
- Brown previously served for 10 years on the Board of directors of Brown-Forman Corporation, a large American wine and spirits company listed on the New York Stock Exchange.
- "Martin brings tremendous legal, health care and civic experience to Cumberland's Board of Directors," said A.J.
- Cumberland Pharmaceuticals Inc. is a specialty pharmaceutical company focused on the delivery of high-quality, prescription brands designed to improve patient care.